The role of staphylococcal polysaccharide microcapsule expression in septicemia and septic arthritis.
Staphylococcus aureus arthritis is a rapidly progressive and highly erosive disease of the joints in which both host and bacterial factors are of pathogenic importance. One potential bacterial virulence factor is the ability to express a polysaccharide capsule (CP). Among 11 reported capsular serotypes, CP type 5 (CP5) and CP8 comprise 80 to 85% of all clinical blood isolates. The aim of this study was to assess the role of CP5 as a virulence factor in staphylococcal septicemia and septic arthritis with a recently established murine model of hematogenously spread S. aureus arthritis. NMRI mice were inoculated intravenously with S. aureus strains isogenic for expression of CP5, and clinical, bacteriological, serological, and histopathological progression of disease was studied. Inoculation of 7 x 10(6) CFU of S. aureus per mouse induced 55% mortality in the group inoculated with the CP-expressing bacteria, compared to 18% in the group inoculated with CP- mutants. A lower dose of inoculum (3 x 10[6] per mouse) did not give rise to mortality in mice inoculated with CP mutant strains, whereas 18% of the mice inoculated with the CP5-expressing S. aureus died. Importantly, mice inoculated with S. aureus expressing CP5 had a significantly higher frequency of arthritis and a more severe form of the disease. In vitro assays suggested that macrophages were not able to phagocytize CP5+ staphylococci as efficiently as they were CP5- strains. In addition, once phagocytized, CP5+ bacteria were less efficiently killed than CP- mutants. In summary, CP5 leads to a higher frequency of arthritis and a more severe course of the disease. This seems to be related to the effects of the downregulatory properties of CP on the ingestion and intracellular killing capacity of phagocytes. Our results clearly indicate that the expression of CP5 is a determinant of the virulence of S. aureus in arthritis and septicemia.
Nilsson
I M
IM
Department of Rheumatology, University of Göteborg, Sweden.
Lee
J C
JC
Bremell
T
T
Rydén
C
C
Tarkowski
A
A
D000818:Animals; D001170:Arthritis, Infectious / Q000382:microbiology* / Q000401:mortality / Q000473:pathology; D016667:Bacterial Capsules; D001835:Body Weight; D004195:Disease Models, Animal; D016326:Extracellular Matrix Proteins / Q000378:metabolism; D007371:Interferon-gamma / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D007596:Joints / Q000473:pathology; D008264:Macrophages / Q000382:microbiology; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D010587:Phagocytosis; D011485:Protein Binding; D018805:Sepsis / Q000382:microbiology* / Q000401:mortality / Q000473:pathology; D013203:Staphylococcal Infections / Q000382:microbiology* / Q000401:mortality / Q000473:pathology; D013211:Staphylococcus aureus / Q000472:pathogenicity*
D016326:Extracellular Matrix Proteins; D015850:Interleukin-6; D007371:Interferon-gamma